Lancet Oncology, 1470-2045


View graph of relations

Related Publications
  1. Improving affordability of new Essential Cancer Medicines

    t'Hoen, E., Meyer, S., Durisch, P., Bannenberg, W., Perehudoff, K., Reed, T. & Barber, M. J., Aug-2019, In : Lancet Oncology. 20, 8, p. 1052-1054 4 p.

    Research output: Contribution to journalEditorialAcademicpeer-review

  2. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial

    FaMRIsc Study Grp, Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., van Zuidewijn, D. B. W. D. R., Zonderland, H. M., Tollenaar, R. A. E. M., Lobbes, M. B., Ausems, M. G. E. M., van t'Riet, M., Hooning, M. J., Mares-Engelberts, I., Luiten, E. J. T., Heijnsdijk, E. A. M., Verhoef, C., Karssemeijer, N., Oosterwijk, J. C., Obdeijn, I-M., de Koning, H. J. & Tilanus-Linthorst, M. M. A., Aug-2019, In : Lancet Oncology. 20, 8, p. 1136-1147 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

    Banerji, U., van Herpen, C. M. L., Saura, C., Thistiethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., Rottey, S., Geenen, J., Eskens, F., Gil-Martin, M., Mommers, E. C., Koper, N. P. & Aftimos, P., Aug-2019, In : Lancet Oncology. 20, 8, p. 1124-1135 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    CheckMate 214 investigators, Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B., Melichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M-O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S. & Tannir, N. M., Oct-2019, In : Lancet Oncology. 20, 10, p. 1370-1385 16 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

    PORTEC study group, de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'Amico, R., Fyles, A., Baron, M-H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., Hanzen, C., Kruitwagen, R. F., Smit, V. T. H. B. M., Singh, N., Do, V., Lissoni, A., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H. & Creutzberg, C. L., Sep-2019, In : Lancet Oncology. 20, 9, p. 1273-1285 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (74) »

ID: 1566534